Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Outcome
Results posted; no analysis attached
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
9 July 2020
Ended
11 April 2024
Enrollment
93 participants
Sites
9
Primary outcomes
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs); Percentage of Participants Based on Severity of Treatment-emergent Adverse Events; Number of Participants With Dose-limiting Toxicities (DLTs)
Sponsor type
Industry
Results posted
29 May 2025
Last update
29 May 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 29 May 2025
Primary outcome
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Part A: Ginisortamab 100 mg: 100, n = 3Part A: Ginisortamab 250 mg: 100, n = 5Part A: Ginisortamab 500 mg: 100, n = 5Part A: Ginisortamab 1000 mg: 100, n = 6Part A: Ginisortamab 2000 mg: 100, n = 6Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D: 87.5, n = 8Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D: 100, n = 8Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D: 87.5, n = 8Values: percentage of participantsTime frame: From Baseline until the End of Study (up to 3.8 years)No analysis posted for this outcome (outcome 1)
Primary outcome
Percentage of Participants Based on Severity of Treatment-emergent Adverse EventsNCI CTCAE grade >=3 TEAEs: Part A: Ginisortamab 100 mg: 66.7, n = 3NCI CTCAE grade >=3 TEAEs: Part A: Ginisortamab 250 mg: 40.0, n = 5NCI CTCAE grade >=3 TEAEs: Part A: Ginisortamab 500 mg: 40.0, n = 5NCI CTCAE grade >=3 TEAEs: Part A: Ginisortamab 1000 mg: 0, n = 6NCI CTCAE grade >=3 TEAEs: Part A: Ginisortamab 2000 mg: 50.0, n = 6NCI CTCAE grade >=3 TEAEs: Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D: 62.5, n = 8NCI CTCAE grade >=3 TEAEs: Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D: 50.0, n = 8NCI CTCAE grade >=3 TEAEs: Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D: 37.5, n = 8NCI CTCAE grade >=3 related TEAEs: Part A: Ginisortamab 100 mg: 0, n = 3NCI CTCAE grade >=3 related TEAEs: Part A: Ginisortamab 250 mg: 0, n = 5NCI CTCAE grade >=3 related TEAEs: Part A: Ginisortamab 500 mg: 0, n = 5NCI CTCAE grade >=3 related TEAEs: Part A: Ginisortamab 1000 mg: 0, n = 6NCI CTCAE grade >=3 related TEAEs: Part A: Ginisortamab 2000 mg: 0, n = 6NCI CTCAE grade >=3 related TEAEs: Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D: 0, n = 8NCI CTCAE grade >=3 related TEAEs: Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D: 0, n = 8NCI CTCAE grade >=3 related TEAEs: Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D: 0, n = 8Values: percentage of participantsTime frame: From Baseline until the End of Study (up to 3.8 years)No analysis posted for this outcome (outcome 2)
DLT/MTD
Number of Participants With Dose-limiting Toxicities (DLTs)Part A: Ginisortamab 100 mg: 0 of 3Part A: Ginisortamab 250 mg: 0 of 5Part A: Ginisortamab 500 mg: 0 of 5Part A: Ginisortamab 1000 mg: 0 of 6Part A: Ginisortamab 2000 mg: 0 of 6Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D: 0 of 8Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D: 0 of 8Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D: 0 of 8Values: ParticipantsTime frame: From Baseline throughout 28 days (Cycle 1)No analysis posted for this outcome (outcome 3)
Participants
Part A: Ginisortamab 100 mg: 3 started, 1 completedPart A: Ginisortamab 250 mg: 5 started, 1 completedPart A: Ginisortamab 500 mg: 5 started, 2 completedPart A: Ginisortamab 1000 mg: 6 started, 3 completedPart A: Ginisortamab 2000 mg: 6 started, 3 completedPart A1: Ginisortamab 2000 mg Q2W (60-min), 28D: 8 started, 1 completedPart A1: Ginisortamab 2000 mg Q2W (30-min), 28D: 8 started, 4 completedPart A1: Ginisortamab 3000 mg Q3W (90-min), 21D: 8 started, 5 completedPart A1: Ginisortamab 4000 mg Q4W (120-min), 28D: 8 started, 2 completedPart B: Ginisortamab 500 mg + TFD/TPI SoC: 9 started, 5 completedPart B: Ginisortamab 1000 mg + TFD/TPI SoC: 4 started, 3 completedPart B: Ginisortamab 2000 mg + TFD/TPI SoC: 8 started, 3 completedPart C: Ginisortamab 500 mg + mFOLFOX6 SoC: 5 started, 3 completedPart C: Ginisortamab 1000 mg + mFOLFOX6 SoC: 3 started, 2 completedPart C: Ginisortamab 2000 mg + mFOLFOX6 SoC: 7 started, 0 completed
Serious adverse events
Part A: Ginisortamab 100 mg: 2 of 3Part A: Ginisortamab 250 mg: 3 of 5Part A: Ginisortamab 500 mg: 1 of 5Part A: Ginisortamab 1000 mg: 0 of 6Part A: Ginisortamab 2000 mg: 1 of 6Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D: 1 of 8Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D: 2 of 8Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D: 2 of 8Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D: 5 of 8Part B: Ginisortamab 500 mg + TFD/TPI SoC: 4 of 9Part B: Ginisortamab 1000 mg + TFD/TPI SoC: 2 of 4Part B: Ginisortamab 2000 mg + TFD/TPI SoC: 4 of 8Part C: Ginisortamab 500 mg + mFOLFOX6 SoC: 5 of 5Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC: 1 of 3Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC: 2 of 7Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Cycle 1 Day 1 EOI: Part A: Ginisortamab 100 mg 18.0477 (10.0206), n=3; Part A: Ginisortamab 250 mg 72.5261 (24.1924), n=5; Part A: Ginisortamab 500 mg 130.7757 (14.1088), n=4; Part A: Ginisortamab 1000 mg 277.5536 (10.8287), n=5; Part A: Ginisortamab 2000 mg 552.3530 (19.5548), n=6; Part A1: Ginisortamab 2000 mg Q2W (60-m… 592.2331 (26.1556), n=8; Part A1: Ginisortamab 2000 mg Q2W (30-m… 593.1846 (22.2154), n=8; Part A1: Ginisortamab 3000 mg Q3W (90-m… 946.0883 (19.3798), n=8 [geometric mean microgram per milliliter (ug/mL), Geometric Coefficient of Variation] (first of 4 rows)
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Cycle 1 Day 1 EOI: Part B: Ginisortamab 500 mg + TFD/TPI S… 104.0606 (15.3565), n=7; Part B: Ginisortamab 1000 mg + TFD/TPI… 250.8708 (7.6032), n=4; Part B: Ginisortamab 2000 mg + TFD/TPI… 463.5265 (28.6333), n=7; Part C: Ginisortamab 500 mg + mFOLFOX6… 122.8221 (14.8778), n=5; Part C: Ginisortamab 1000 mg + mFOLFOX6… 175.0745 (34.7390), n=3; Part C: Ginisortamab 2000 mg + mFOLFOX6… 471.9576 (17.1727), n=7 [geometric mean ug/mL, Geometric Coefficient of Variation] (first of 4 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) [From Baseline until the End of Study (up to 3.8 years)]. Number, percentage of participants. Part A: Ginisortamab 100 mg (n=3): 100; Part A: Ginisortamab 250 mg (n=5): 100; Part A: Ginisortamab 500 mg (n=5): 100; Part A: Ginisortamab 1000 mg (n=6): 100; Part A: Ginisortamab 2000 mg (n=6): 100; Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 87.5; Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 100; Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D (n=8): 87.5; Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D (n=8): 100; Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 100; Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 100; Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 100; Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 100; Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 100; Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 100.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Percentage of Participants Based on Severity of Treatment-emergent Adverse Events [From Baseline until the End of Study (up to 3.8 years)]. Number, percentage of participants. NCI CTCAE grade >=3 TEAEs: Part A: Ginisortamab 100 mg (n=3): 66.7; Part A: Ginisortamab 250 mg (n=5): 40.0; Part A: Ginisortamab 500 mg (n=5): 40.0; Part A: Ginisortamab 1000 mg (n=6): 0; Part A: Ginisortamab 2000 mg (n=6): 50.0; Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 62.5; Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 50.0; Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D (n=8): 37.5; Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D (n=8): 62.5; Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 55.6; Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 75.0; Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 87.5; Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 100; Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 100; Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 85.7. NCI CTCAE grade >=3 related TEAEs: Part A: Ginisortamab 100 mg (n=3): 0; Part A: Ginisortamab 250 mg (n=5): 0; Part A: Ginisortamab 500 mg (n=5): 0; Part A: Ginisortamab 1000 mg (n=6): 0; Part A: Ginisortamab 2000 mg (n=6): 0; Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 0; Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 0; Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D (n=8): 0; Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D (n=8): 12.5; Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 22.2; Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 0; Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 25.0; Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 40.0; Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 0; Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 14.3.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Participants With Dose-limiting Toxicities (DLTs) [From Baseline throughout 28 days (Cycle 1)]. Count Of Participants, Participants. Part A: Ginisortamab 100 mg (n=3): 0; Part A: Ginisortamab 250 mg (n=5): 0; Part A: Ginisortamab 500 mg (n=5): 0; Part A: Ginisortamab 1000 mg (n=6): 0; Part A: Ginisortamab 2000 mg (n=6): 0; Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 0; Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 0; Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D (n=8): 0; Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D (n=8): 0; Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 1; Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 0; Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 1; Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 0; Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 0; Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort [Parts A: Cycle 1 (Day 1 end of infusion [EOI] and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose); Part A 1: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose)]. Geometric Mean, microgram per milliliter (ug/mL) (Geometric Coefficient of Variation). Cycle 1 Day 1 EOI: Part A: Ginisortamab 100 mg (n=3): 18.0477 (10.0206); Part A: Ginisortamab 250 mg (n=5): 72.5261 (24.1924); Part A: Ginisortamab 500 mg (n=5): 130.7757 (14.1088); Part A: Ginisortamab 1000 mg (n=6): 277.5536 (10.8287); Part A: Ginisortamab 2000 mg (n=6): 552.3530 (19.5548); Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 592.2331 (26.1556); Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 593.1846 (22.2154); Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D (n=8): 946.0883 (19.3798); Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D (n=8): 1357.6103 (20.4135). Cycle 1 Day 15 Predose: Part A: Ginisortamab 100 mg (n=3): 4.4210 (10.1288); Part A: Ginisortamab 250 mg (n=5): 12.8115 (27.1385); Part A: Ginisortamab 500 mg (n=5): 24.3743 (31.2011); Part A: Ginisortamab 1000 mg (n=6): 61.4527 (33.1491); Part A: Ginisortamab 2000 mg (n=6): 92.0396 (38.4595); Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 105.5277 (25.1756); Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 97.1957 (39.3439). Cycle 2 Day 1 Predose: Part A: Ginisortamab 100 mg (n=3): NA (NA) [GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.]; Part A: Ginisortamab 250 mg (n=5): NA (NA) [GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.]; Part A: Ginisortamab 500 mg (n=5): 34.6409 (26.9986); Part A: Ginisortamab 1000 mg (n=6): 67.0799 (37.9557); Part A: Ginisortamab 2000 mg (n=6): 149.3886 (37.0769); Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D (n=8): 193.4242 (34.5942); Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D (n=8): 147.2154 (26.4979); Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D (n=8): 124.7274 (44.3198); Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D (n=8): 98.9331 (33.8567). Cycle 2 Day 15 Predose: Part A: Ginisortamab 100 mg (n=3): NA (NA) [GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.]; Part A: Ginisortamab 250 mg (n=5): NA (NA) [GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.]; Part A: Ginisortamab 500 mg (n=5): 42.6861 (38.1929); Part A: Ginisortamab 1000 mg (n=6): 78.2336 (35.0467); Part A: Ginisortamab 2000 mg (n=6): 166.4011 (34.1041).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level [Part B and C: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose)]. Geometric Mean, ug/mL (Geometric Coefficient of Variation). Cycle 1 Day 1 EOI: Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 104.0606 (15.3565); Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 250.8708 (7.6032); Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 463.5265 (28.6333); Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 122.8221 (14.8778); Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 175.0745 (34.7390); Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 471.9576 (17.1727). Cycle 1 Day 15 Predose: Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 19.7473 (42.6072); Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 37.4171 (14.8496); Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 83.4236 (30.8533); Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 16.8917 (33.2664); Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 32.3094 (56.2327); Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 70.7026 (50.9842). Cycle 2 Day 1 Predose: Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 33.0061 (35.3957); Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 61.0398 (5.0117); Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 118.0926 (29.3051); Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 25.4863 (53.6347); Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): 82.7657 (47.9648); Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 141.6084 (30.8310). Cycle 2 Day 15 Predose: Part B: Ginisortamab 500 mg + TFD/TPI SoC (n=9): 38.3595 (42.1013); Part B: Ginisortamab 1000 mg + TFD/TPI SoC (n=4): 55.0249 (39.4082); Part B: Ginisortamab 2000 mg + TFD/TPI SoC (n=8): 135.5849 (32.8644); Part C: Ginisortamab 500 mg + mFOLFOX6 SoC (n=5): 24.7120 (83.6183); Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC (n=3): NA (NA) [GeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.]; Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC (n=7): 135.0042 (43.8716).